Reducing race differences in direct-to-consumer pharmaceutical advertising : the case for regulation /

This book examines whether direct-to-consumer pharmaceutical advertising changed in response to recommendations made by the FDA in 2009 to enhance the informational and motivational value of advertising to be more accessible to minority populations and consequently work to reduce health disparities.

Bibliographic Details
Call Number:Libro Electrónico
Main Authors: De Scisciolo, Stephany, 1958- (Author), Scheid, Teresa L. (Author)
Format: Electronic eBook
Language:Inglés
Published: Lanham, Maryland : Lexington Books, an imprint of The Rowman & Littlefield Publishing Group, Inc., [2018]
Subjects:
Advertising > Drugs > United States.
Direct-to-consumer prescription drug advertising > United States.
Discrimination in the advertising industry > United States.
Discrimination in medical care > United States.
Médicaments > Publicité > États-Unis.
Publicité directe des médicaments d'ordonnance > États-Unis.
Discrimination dans les soins médicaux > États-Unis.
BUSINESS & ECONOMICS > Advertising & Promotion.
Advertising > Drugs
Direct-to-consumer prescription drug advertising
Discrimination in medical care
Discrimination in the advertising industry
United States
Online Access:Texto completo
Table of Contents:
  • Introduction: health disparities and pharmaceutical advertising
  • The pharmaceutical industry, direct to consumer advertising, and racial differences
  • Direct to consumer advertising: patient empowerment or manipulation?
  • Comparative analysis of the frequency and type of DTCA
  • Differences in the appearance and content of DTCA
  • Examination of the visual content of DTCA
  • Conclusion: a missed opportunity: policy implications.

Similar Items